The use of isotretinoin therapy in dermatology has become complicated by regulatory and medicolegal issues. Still, isotretinoin for severe acne has been a mainstay of dermatologic therapy since its Food and Drug Adminstration approval in 1982. While dermatologists have become adept at addressing the drug's well-known teratogenic adverse effects and potential associations with depression and suicidal ideation, a knowledge gap may exist for many dermatologists to address clinical care questions related to isotretinoin therapy and IBD. The article by Popescu and Popescu1 in this issue of Archives helps to narrow this gap and potential knowledge gaps related to general epidemiologic principles about causation.
Mostow EN. Include Discussions and Review of Systems Regarding Inflammatory Bowel Disease in Patients Starting Isotretinoin TherapyComment on “Isotretinoin Therapy and Inflammatory Bowel Disease”. Arch Dermatol. 2011;147(6):729-730. doi:10.1001/archdermatol.2011.131